Prof Andrew Abell
The University of Adelaide
Prof Abell’s research is concerned with the design, synthesis, and exploitation of small molecule enzyme inhibitors and mimics of key biological compounds (particularly peptides) as a basis of new therapeutics for protease-related diseases, cancer and other diseases and infections; as well as probes to study and exploit key metabolic processes such as electron transfer. He has had a leading role in initiatives that foster extended multidisciplinary research including as a founding member of Institute for Photonics and Advanced Sensing (IPAS), a past head of school of Chemistry and Physics (University of Adelaide), Adelaide node director ARC Centre of Excellence for Nanoscale BioPhotonics (CNBP) in what is a truly world-class multidisciplinary research environment. He is a co-founder of Calpain Therapeutics, a privately-funded biotechnology venture dedicated to the development of proprietary candidate drug compounds having the potential to impact the progression of major ophthalmic diseases and enhance the quality of patients’ lives.